The Biotest Group has grown its core business continuously over recent years. We want to continue along this path at a faster pace. Our strategy encompasses six elements:
Consistent focus
Biotest focuses on biological drugs in the therapeutical areas of haematology, clinical immunology and intensive care medicine and continuously expands its product range in these fields.
Coverage of the entire process and value chain
Biotest operates across most of the process and value chain with its own resources. This encompasses research and development, collection of a substantial share of the blood plasma needed for its products in proprietary plasmapheresis centres, manufacture of plasma proteins, as well as quality control and sales.
Research and development
Biotest invests significantly in new and further development of products in its three therapeutic areas. In this process we concentrate on key indications with high therapeutic need.
This is described in more detail under "Research and development".
Continued international expansion
Following our successful establishment in important European markets, Biotest is now focused on further expanding its positions in the USA, Asia and South America. We achieve this via authorisation for specific products and by expanding our sales structures.